Comparison of model-based dose escalation design with rule-based design of phase I oncology trials

被引：0
|
作者：
Shimomura, A. [1 ]
Ebata, T. [1 ]
Koyama, T. [1 ]
Iwasa, S. [1 ]
Kondo, S. [1 ]
Kitano, S. [1 ]
Yonemori, K. [1 ]
Fujiwara, Y. [1 ]
Shimizu, T. [1 ]
Yamamoto, N. [1 ]
机构：
[1] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The performance of model-based versus rule-based phase I clinical trials in oncology A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years
    van Brummelen, E. M. J.
    Huitema, A. D. R.
    van Werkhoven, E.
    Beijnen, J. H.
    Schellens, J. H. M.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 (03) : 235 - 242
  • [2] DESIGNING OF PHASE I ONCOLOGY DOSE ESCALATION USING DOSE-EXPOSURE-TOXICITY MODEL AS A COMPLEMENTARY APPROACH TO RULE-BASED OR MODEL-BASED DOSE-TOXICITY MODELS.
    Pantoja, K.
    Lanke, S.
    Munafo, A.
    Victor, A.
    Habermehl, C.
    Schueler, A.
    Venkatakrishnan, K.
    Girard, P.
    Goteti, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S65 - S65
  • [3] The performance of model-based versus rule-based phase I clinical trials in oncologyA quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years
    E. M. J. van Brummelen
    A. D. R. Huitema
    E. van Werkhoven
    J. H. Beijnen
    J. H. M. Schellens
    [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43 : 235 - 242
  • [4] Flexible, rule-based dose escalation: The cohort-sequence design
    Li, Shuang
    Xie, Xian-Jin
    Heitjan, Daniel F.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 17
  • [5] Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
    Ron J. Keizer
    Anthe S. Zandvliet
    Jos H. Beijnen
    Jan H. M. Schellens
    Alwin D. R. Huitema
    [J]. Investigational New Drugs, 2012, 30 : 1519 - 1530
  • [6] Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
    Keizer, Ron J.
    Zandvliet, Anthe S.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Huitema, Alwin D. R.
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1519 - 1530
  • [7] TEAMS: Toxicity- and Efficacy-Based Dose-Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology
    Guo W.
    Ni Y.
    Ji Y.
    [J]. Statistics in Biosciences, 2015, 7 (2) : 432 - 459
  • [8] THE COMPARISON OF THE EFFECTIVENESS OF MODEL-BASED SRAFS AND RULE-BASED SRAFS
    Du, Yaojun
    [J]. 2016 CHINA SEMICONDUCTOR TECHNOLOGY INTERNATIONAL CONFERENCE (CSTIC), 2016,
  • [9] AN INTEGRATED MODEL-BASED AND RULE-BASED APPROACH TO DESIGN OF AUTOMATIC SWITCHING FOR SUBTRANSMISSION LINES
    MA, TK
    LIU, CC
    DAMBORG, M
    CHANG, M
    [J]. IEEE TRANSACTIONS ON POWER SYSTEMS, 1994, 9 (02) : 750 - 756
  • [10] Flexible, rule-based dose escalation: The cohort-sequence design (vol 17, 100541, 2020)
    Li, S.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 20
12345